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Abstract  
 
 
Background 
Schizophrenia usually onsets from late adolescence to the third decade of life (Early-
Onset Schizophrenia), although it may onset during childhood or later in adult life 
(15%-23,5% >40 years and 3%-4% >60 years). Late-Onset Schizophrenia (LOS) is 
the term applied to the rare cases of Schizophrenia whose diagnosis is made after 40 
years of age. 
Given the lack of studies gathering the multiple areas of data about LOS, we found 
pertinent to review this theme. The main goal of this article is, then, to review 
knowledge available for LOS, namely its clinics, risk factors, delaying factors for 
Schizophrenia (including recent findings at the molecular level), prognosis and its 
association with organic central nervous system disease. This will be done 
emphasizing similarities and disparities relative to EOS which may contribute to the 
central debate about etiopathogenic differences/resemblances between both patient 
groups. 
 
Methods 
A database search on PubMed Articles published between 1 January 2005 and 31 
December 2011 was undertaken, based on research keywords: “late-onset 
schizophrenia”, “late onset schizophrenia”, “late-onset psychosis” and “paraphrenia”. 
In addition, we screened related studies and reference lists of identified studies. We 
included studies published in English and French. 
 
Results 
The systematic search yielded a total of 241 unique studies. After the screening of 
titles and abstracts, the full article assessment and the adding of relevant references, a 
total of 50 studies revealed to be of interest and provided the base for the present 
systematic review.  
 
Conclusions 
Great difficulties remain inherent in the study of LOS, arising from lack of works in 
this population and from discrepancies among them in what concerns study designs 
and methods of analysis. 
There are well-established differences in clinical features between LOS and EOS 
patients, attributing clinical utility to this subdivision of Schizophrenia.  
It has been described a molecular factor specifically associated with LOS and not 
with Schizophrenia in general – CCR5 32bp deletion allele. 
Subdivision of Schizophrenia proposed by the International Consensus remains 
unclear about its pathophysiologic validity, as current evidence points to the 
possibility of LOS representing a heterogeneous group of patients, including delayed 
forms of EOS and distinct pathogenic entities.  
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Background  
 
Schizophrenia is a clinical syndrome characterized by a profoundly disruptive 
psychopathology that involves cognition, emotion, perception, and other aspects of 
behavior. It affects roughly 1% of world population and it usually onsets from late 
adolescence to the third decade (Early-Onset Schizophrenia - EOS), although in a 
significant portion of cases symptoms begin during childhood (4% <18 years) or later in 
adult life (15%-23,5% >40 years and 3%-4% >60 years), and even at 100 years of age. 
[1-3].  
Manfred Bleuler, in 1943, studying the particularities of patients whose 
symptoms developed later in life, was the first to suggest a clinical subdivision of 
Schizophrenia by age of onset [4]. However, this subdivision was neither widely 
adopted nor criteria-consistent in the scientific community, including between 
International Classification of Diseases (ICD) and Diagnostic and Statistical Manual of 
Mental Disorders (DSM) [5-7]. Only in 2000 the “International Consensus” postulated 
diagnostic distinction of later-onset cases by reviewing the rationale about their validity 
and clinical utility. This document, elaborated following the gathering and agreement of 
experts in the matter constituted an evidence-based attempt to overcome the discordance 
in this subject and to stimulate research about the specificities of these groups of 
patients. It classified cases of later onset of Schizophrenia symptomatology either as 
Late-Onset Schizophrenia (LOS) and Very-Late-Onset Schizophrenia-Like Psychosis 
(VLOSP). Late-Onset Schizophrenia (LOS), the subject of this work, was then defined 
as cases in which Schizophrenia criteria are met after the 40 years of age but before 60 
years of age (the cut-off age for VLOSP).  
Underlying the study of the clinical and epidemiologic particularities of LOS is 
also the question of its etiopathogeny. In the case of EOS, from which much more 
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studies are available, the question of etiopathogeny remains largely unknown, despite 
being generally accepted to be due to a neurodevelopment defect [8]. Hence, if we aim 
to understand etiology and pathological mechanisms leading to LOS, the first big 
problem concerns the extent to which its underlying mechanisms are different from 
EOS. From this point of view, several questions may be raised, which may not be 
mutually exclusive: is LOS a delayed form of EOS or does it constitute a distinct 
mechanistic entity? If the pathologic processes are the same, what explains the later 
onset of the disorder? If the pathologic processes are not the same, in which degree is 
the etiopathogeny different from the typical Schizophrenia cases? Is there a pathological 
role played by Central Nervous System (CNS) aging in the development of LOS? Is 
there any contributing role played by neurodegenerative and cerebrovascular diseases? 
Is there any kind of role for gender? Can the answer be a combination of some of the 
previous hypothesis? There are different possible approaches that may give clues to the 
questions above, and they range from the molecular to the clinical level 
We found the theme of LOS important to review given (1) the lack of recent 
works gathering latest knowledge about its clinics, epidemiologic and biologic 
specificities; (2) also because of the interesting debate that its etiopathophysiology 
permits, since it is a group of patients whose age is situated between the non-organic 
EOS group and the recognized organic forms constituting VLOSP.  
So, the main goal of this article is to review the data available for LOS, namely 
its clinics, risk factors, delaying factors of Schizophrenia, prognosis and possible 
associations with organic central nervous system disease. This will be done 
emphasizing similarities and disparities of the same data relative to the EOS-group, in 
order to discuss the questions mentioned above, related to possible ethiopathogenic 
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similarities and differences between LOS and EOS. Also, inherent in research on the 
topic there are numerous difficulties which will be addressed initially in the article.  
 
Methods 
 
Literature search 
 
A database search on PubMed Articles published between 1 January 2005 and 
31 December 2011 was undertaken, based on research keywords: “late-onset 
schizophrenia”, “late onset schizophrenia”, “late-onset psychosis” and “paraphrenia”. 
The literature search yielded the identification of 371 possibly eligible articles. 
  
Eligibility assessment 
 
A stepwise approach was used in the selection process. First, each title and 
abstract were screened in accordance with the following inclusion criteria that were 
developed a priori: (1) Study participants must have a medical diagnosis of 
Schizophrenia, LOS, VLOSP or Paraphrenia; (2) Studies must be written in English, 
French, or Portuguese. Second, studies were excluded if they focused only in 
characteristics within Early-Onset Schizophrenia cases. Third, full articles were also 
read if a title and its abstract did not provide sufficient information for exclusion. 
Finally, relevant references were considered. 
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Results  
 
The systematic search yielded a total of 241 unique studies. After screening of 
titles and abstracts, 39 were considered potentially relevant. After the full article 
assessment, 35 articles were retrieved. Also, 15 relevant references were added. A total 
of 50 studies revealed to be of interest and provided the base for the present systematic 
review (Figure 1). 
 
Discussion 
 
LOS research difficulties and the International Consensus 
 
A considerable amount of obstacles are inherent to LOS research, some of them 
expectable given the previously mentioned discrepancies in the scientific community in 
the “pre-Consensus era” in what concerns to the subject. These difficulties may be 
schematized as: (1) discrepancy in the terminology and criteria used to define LOS 
patients, (2) poor research using this specific population and, finally, (3) lack of 
uniformity on the methods used in the assessment of patients and data analysis [9-12]. 
The general consequences that arise are of two types: significantly increased difficulty 
in the process of bibliographic review and need for meticulous care when trying to 
extrapolate data for LOS from studies that include patients whose symptoms begin later 
in life. 
Terminology used to classify patients whose symptoms begin later in adult life 
show lack of homogeneity since Bleuler . Among the different studies, cases with 
criteria for LOS have been called: “Late-Onset Schizophrenia”, “Late Paraphrenia” 
or a larger group “Late-Onset Psychosis”. [2, 5, 9, 10].  
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The term paraphrenia refers to a condition characterized by a strong delusional  
component with preservation of thought and personality, with a chronic course leading 
to a significant degree of cognitive impairment [13]. Furthermore, some works use the 
term “late paraphrenia” to refer onset after 60 or 65 years old, while others use it to 
differentiate from older chronic Schizophrenia patients or to emphasize the many 
distinguishing features that set apart late-life psychosis from Schizophrenia [13]. 
Late-Onset Psychosis is characterized by a well-organized delusional system, 
with or without hallucinations and with no obvious deterioration in personality or 
intellect, with onset after 40 years old or after 60 years old [14, 15].  
In what concerns LOS criteria, the rare research work that analyses data 
specifically for a group of age of onset (and not Schizophrenia cases as a whole) do not 
always obey to a uniform cut-off to define LOS. The cut-off age to define LOS (found 
in the literature) range from 40 to 65 years of age [15-19]. Adding to this, the number 
and sample sizes of LOS studies compared with those regarding EOS or childhood 
Schizophrenia is scarce [12].  
Our review also found several different criteria among studies to establish this 
age of onset: first psychotic symptoms [5, 9, 15, 17, 20], first contact with psychotic 
service [21, 22], first manifestation of prodromal symptoms [10]. This difficulty may be 
increased in LOS cases due to their less severe symptomatology, which make the 
recognition of the initial symptoms more difficult [10, 12, 23-27]. 
Yet another difficulty relates to the tests used to measure features and the type of 
statistical analysis involved, which may lead to different results [10, 12, 15]. Also, some 
divergent findings could possibly be attributed to the heterogeneity of the studies’ 
samples, which not only included patients with Schizophrenia diagnosed by ICD or 
DSM criteria, but they also included other psychiatry disorders [15].  
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The International Consensus 
 
Taking all these difficulties into account, and in order to stimulate more research 
to better understand the pathophysiology and etiology of schizophrenias, the 
International Late-Onset Schizophrenia Group, in the year 2000, reviewed and 
discussed the evidence about this matter and suggested the recognition of two classes of 
late-onset psychotic disorders based on the age at onset of first psychotic symptoms: a 
Late-Onset Schizophrenia (LOS: onset > 40 years), and a Very-Late-Onset 
Schizophrenia-Like Psychosis (VLOSP: onset > 60 years) [5]. VLOSP replaced both 
terms “Late Paraphrenia” and “Paraphrenia”, and it also includes: Schizophrenia, 
Delusional Disorders, Schizoaffective Disorder, Bipolar Disorder with Psychotic 
Features, Paranoid Psychosis and Psychosis “Not Otherwise Specified”, with age of 
onset after 60 years old [5, 13, 28]. Studies measuring the impact of this document in 
the concordance of diagnostic stratification of Schizophrenia, nomenclature and cut-offs 
used are missing.  
Currently, in ICD-10 (year 1993) and DSM-IV-TR (year 2000) the LOS 
group of patients fall into the category “Schizophrenia”, although DSM-IV-TR refers to 
the cases of Schizophrenia with onset after 45 years of age as having some different 
characteristics from the group of patients whose disorder begins early in life [6, 7]. 
This review article considered LOS as the designation attributed to the group of 
schizophrenic patients whose symptoms begin later than 40 years of age.  
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LOS Clinical features:  
Symptomatology, response to treatment and prognosis 
 
LOS Symptomatology  
 
Diagnostic criteria for LOS corresponds to a set of symptoms similar to those in 
EOS [5].  This fact and the efficacy verified to the same class of drugs (which will be 
discussed later) remain the strongest rational base to hypothesize a mechanistic 
homogeneity between LOS and EOS. DSM-IV-TR and ICD-10 diagnostic criteria for 
Schizophrenia are summarized in tables 1 and 2, respectively. 
Despite obeying to the same diagnostic criteria than EOS, LOS patients show 
some well-established clinical differences in comparison to patients with EOS 
(summarized in table 3). LOS is more often in the female gender [5, 13, 15, 17, 20]; it is 
more likely than EOS to have multimodal hallucinations, systematized delusions, 
persecutory delusions and a better premorbid function [5]; it has less family history of 
Schizophrenia [5, 13, 15]; it is less likely to have thought disorders (specially formal 
thought disorders), affective bluntness, disorganization conducts, severe positive 
symptoms [5, 15].  
Knowledge is still sparse and controversial regarding the LOS cognitive 
performance, with some studies finding no differences between LOS and EOS while 
others found differences in both directions [15]. In order to determine if the chronicity 
effect and extensive use of typical neuroleptics could influence cognitive deficits, a 
meta-analyses compared in-treatment LOS patients with first-episode EOS patients 
[12]. That study found that those LOS patients have more cognitive impairment than 
first-episode EOS ones.  So, the findings concerning differences in cognitive 
performance in LOS versus EOS seem to be susceptible to disparities in time-course of 
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disease and treatment between both patient samples. There are no studies available, 
however, that compare first-episode LOS patients with first-episode EOS patients, 
neither studies that adjust for age and time-course of outpatients. Nevertheless, 
regarding the cognitive profile, LOS seems to have a specific rather than generalized 
cognitive deficits, not explainable only by aging and related factors, which points to 
disturbed circuits being specific rather than generalized in LOS [12].  
Worthy of emphasis is that most of the differences between EOS and LOS that 
we have been discussing remained significant even after adjustments in age, gender, 
severity of negative symptoms, and duration of illness [5]. Also, the hypothesis that 
Deficit Syndrome, a variant of Schizophrenia disorder characterized by enduring, 
idiopathic negative symptoms and more severe course of illness, is over-represented in 
EOS has been ruled out, showing that it does not contribute to the LOS-EOS’ clinical 
differences [5, 10].  
 
LOS response to treatment  
 
It is expected that an equally good response from LOS patients to the same 
treatment used in EOS patients represents the targeting of common pathogenic 
mechanism(s). Additionally, it is not surprising that LOS-patients have been receiving 
similar therapies (both pharmacologic and non-pharmacologic) as this subgroup was 
only recently formally recognized. This led to the observation that the same 
antipsychotic therapy exhibits the similar efficacy between LOS and EOS. 
Antipsychotics are, therefore, a mainstay of LOS therapy [5]. Nonpharmacological 
treatment (including psychological management, social skills training, cognitive-
behavioral treatment) has shown to be a helpful adjunct to pharmacotherapy as in EOS 
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cases [5, 29]. Repetitive transcranial magnetic stimulation efficiently reduces resistant 
auditory hallucinations, both in acute and maintenance treatment, also as in EOS cases 
[30].  
An important and well established characteristic of LOS patients is that a less 
dosage of neuroleptics (
1
/4 to ½) is needed to achieve a same symptomatic improvement 
when comparing to EOS cases [5, 15]. Comparing old age schizophrenic in-treatment 
patients (LOS and chronic EOS patients) with healthy controls, it was verified that the 
formers were not achieving a normal state of functioning, but rather were returning to a 
premorbid state of suboptimal and somewhat impaired function [31].  
Drug treatment should be started at very low doses and increases in dosages 
should be made slowly [2, 5]. Use of depot medication at very low doses may be 
successful in ensuring compliance [5]. With the exception of clozapine, the atypical 
antipsychotic agents are clearly advantageous, because of the reduced likelihood of 
extrapyramidal symptoms and tardive dyskinesia for which elderly patients are at higher 
risk [5, 31]. However, even atypical antipsychotic agents have important side effects, in 
particular on cardiovascular and metabolic function, diabetes, and lipid levels [31]. This 
is an important finding because the most common cause of death among schizophrenics 
is heart disease (like in the general population), yet it has been estimated that persons 
with Schizophrenia on average die 10 years earlier than the general population [32, 33]. 
Despite patients with Schizophrenia do not achieve same symptomatic remission 
with atypical agents than with typical ones, the use of the former is justifiable by the 
reduction of the typical antipsychotic drugs side effects, leading  expectedly to a better 
global health in older schizophrenic patients  [5]. At this point, it is relevant to refer that 
there is a great variety of criteria to define remission, which compromises solid 
conclusions [31]. Therefore, regarding the differences in dosage of antipsychotic drug 
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treatment, it is conceivable that it could be partially attributable to (1) a tendency to 
continue prescribing higher doses to EOS patients (who received their first 
antipsychotic prescription in an era when average dose recommendations were higher 
for first-break psychosis); (2) reflection of the EOS residual ⁄ anchoring effects 
(clinicians being hesitant to change medication doses for clinically stable patients); (3) 
secondary factors, such as episodes of hostility or aggression being less prevalent 
among LOS compared to EOS patients; or (4) an increasing pharmaco-sensitivity due to 
less chronic symptomatology [10, 28]. Nevertheless, answer(s) to these hypotheses are 
still not possible from the data available.  
A new, potentially safer and interesting antipsychotic treatment based on 
estrogen (whose rationale will be discussed later) has been tested in schizophrenic 
patients. However, the results from a clinical trial in which estradiol is administered in 
schizophrenic EOS women are not consistent [34-36]. Moreover there is still 
considerable research to be done to determine the correct dose and duration of use of 
estradiol, its safe use in women and men with Schizophrenia (EOS) with respect to the 
known side effects, and whether it may be used eventually as a stand-alone medication 
rather than as an adjunct [37]. A case reporting estrogen replacement therapy alone in a 
periclimacteric patient with LOS experiencing severe symptoms attained remission 
[38]. A case reporting phytoestrogen (chemical structure similar to estradiol) revealed 
improvement in depressive symptoms of a LOS patient, as adjuvant to atypical 
antipsychotic treatment [39]. 
13 
LOS Prognosis 
 
When we talk about prognosis in the context of Schizophrenia we refer both to 
symptom remission after treatment and also to the chronic course of the disease, 
assessing neurocognitive evolution, i.e. whether dementia develops or not.  
The question of symptom remission in LOS has been treated previously in this 
paper.  
In what concerns to cognitive course, cross sectional studies have not found 
accelerated cognitive decline in the lifespan of patients with LOS when compared with 
healthy controls.   
Other studies compared chronically hospitalized Schizophrenia cases with 
outpatients. Particularly, one study that compared chronically hospitalized LOS patients 
with EOS patients and, observed that during their clinical evolution, the first patients 
were more likely to suffer cognitive deficits (frequently of executive functions and 
thought disorder) than EOS patients [40]. On the other hand, in what concerns the 
course of cognitive performance in chronically hospitalized EOS patients when 
comparing to LOS cases, some studies have shown that there is a decrease in the test 
performance of permanently hospitalized patients with chronic Schizophrenia as age 
and illness duration increased; contrarily, LOS patients showed no significant cognitive 
decline after several years of follow-up [41]. This study also adjusts for age and years of 
evolution. This better prognosis found by some works makes it questionable whether 
the results would be the same after adjustment for the effect of ageism, the tendency to 
underdiagnose and undertreat older people [5, 31, 42]. Together with the previous data, 
this may suggest that Schizophrenia prognosis depends more on the severity of its 
clinical features (and, hence, to the activity of the pathologic processes) and not in the 
age context (CNS maturity and aging) in which the disorder onsets. In other words, the 
14 
age of onset seems not to shape clinical phenotype of Schizophrenia (at least in the long 
term). Ignoring some expectable non-adjustable differences between chronically 
institutionalized patients and outpatients with Schizophrenia, these previous findings 
may suggest that EOS and LOS-associated mechanisms have a chronic deleterious 
impact in the functionality and/or integrity of pathways involved in cognition, at least in 
severe forms. Curiously, a recent prospective study analyzed the issue of cognitive 
decline in later age of onset of Schizophrenia with a strong sample of near 8000 cases of 
LOS and VLOSP patients [22]. With a follow-up of 3 to 4 ½ years, they found two to 
three times more risk of dementia in LOS patients when comparing to age-matched 
osteoarthritis patients. If this association is due to course of disease, association with 
other neurodegenerative diseases or with protection from osteoarthritis patients is not 
yet possible to tell. On the other side, exhaustive neuropsychological data to evaluate 
dementia in the initial diagnosis of Schizophrenia is not postulated and was not done in 
this study.  
The impact of Schizophrenia (at least in its severe forms) found by some studies 
seems not to be due to an accelerated process of aging since most neuroimaging 
abnormalities associated with aging are not shared with LOS subgroup, with the 
exception of thalamic enlargement, a feature not observed in EOS patients (table 4). 
Hence, either pathologic processes underlying LOS are different from EOS (namely 
those affecting cognitive pathways) and accelerate some features associated with CNS 
aging (i.e. thalamic enlargement) or Schizophrenia in general has its own ways to 
deteriorate cognitive function, at least in their severe forms, and those are independent 
of ageing.  
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Nevertheless, more studies in the matter are needed as currently it seems not 
possible to have a solid amount of data to address the question of neurocognitive 
evolution in LOS, and comparative to EOS.  
Given the general observations of less severe symptomatology, less doses 
required to achieve same clinical response and that severity-adjusted groups of EOS and 
LOS experience similar cognitive decline, the following questions about etiopathogeny 
of LOS relative to that of EOS become pertinent: can these differences be derived to 
LOS constituting a delayed and more attenuated form of the same perturbed 
mechanisms? Or is LOS a form of Schizophrenia associated with its own pathogenic 
mechanisms that dictate these clinical differences relative to EOS?  
Some data indicate that differences in symptom profiles with onset across the 
age span could represent: (1) cohort difference; (2) age-associated central nervous 
system differences independent of the illness; (3) differences in pathophysiology or 
etiology, thus constituting LOS an etiologically and mechanistically distinct group of 
patients [5]. 
Several approaches are possible when trying to answer these questions and those 
require studies taking into account specific ages of onset of Schizophrenia (in this case 
>40 years old vs <40 years of age). Possible approaches would be the search for 
resemblances and differences between their risk and protective factors, neuro-imaging 
abnormalities, clinical course of disease and statistical association with organic CNS 
disease (not typical of EOS). The neuroimaging approach was already briefly mentioned 
and we found it prudent not to discuss comparative pathophysiology based on this 
parameter because many of the neuroimaging abnormalities have an unclear 
pathological role and uncertain cause-effect relationship. 
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The hypothesis of LOS being a delayed form of EOS would make pertinent the 
search for protective/delaying factors of Schizophrenia. Some risk factors and delaying 
factors for Schizophrenia have emerged and will be discussed hereafter. 
 
LOS known risk and delaying factors 
   
Risk Factors 
 
The importance of studying the risk factors for LOS (and Schizophrenia in 
general) derives not only from identifying potentially predictive, modifiable and 
avoidable factors, but also from the need for a etiopathogenic point of view (essential 
for studying better treatment targets). The degree of risk factors’ overlap between EOS 
and LOS could give hints to the degree of overlap between their etiopathogenies:  
similar risk factors would point LOS more as a delayed form of EOS and different risk 
factors would suggest alternative/additional etiopathogenic mechanisms leading to LOS.  
The only study that systematically reviewed risk factors specifically for LOS 
patients concluded that the strongest predictors were: (1) history of psychotic 
symptoms, (2) cognitive deficits, (3) poor health status, (4) visual impairment, and (5) 
negative life events; older age, female gender, most socio‐demographic indicators, 
premorbid personality traits, positive psychiatric history, substance‐related disorders, 
and hearing impairment were not associated with psychosis in older patients [11]. A 
cohort study based on child survivors of the Holocaust also suggests an influence of 
stress exposure to LOS cases [43]. Social isolation that precedes LOS may be a 
prodromal phase instead of a risk factor, as behavioral studies from ablation studies 
suggest that it may be early manifestations of uncal pathology [44]. 
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* [EMBL: ENSG00000160791] 
Hormonal changes, neuropsychological alterations, and abnormal findings on 
brain imaging may also be important risk factors, however they are not well studied on 
a longitudinal basis [11]. Thus, these data demonstrated that there seems not to be an 
entire overlap between EOS and LOS risk factors, presented by the lack of association 
between LOS and premorbid personality traits, positive psychiatric history and 
substance‐related disorders. However, from a mechanistic point of view, this data has to 
be interpreted with caution since theoretically different factors may act through similar 
targets, perturbing the same pathologically-relevant processes. 
On the genetic level, some molecular factors have recently emerged. One 
biologic risk factor is worthy of note since that it constitutes the only biological factor 
specifically associated with LOS and not with EOS:  chemokine receptor type 5 
(CCR5)* 32-bp deletion allele. We emphasize that this genetic risk factor is associated 
to LOS when comparing to both general population and early-onset cases. 
CCR5 is an immunological receptor and binds a considerable number of 
chemokines. It is also the major co-receptor for the macrophage - infecting strains of 
HIV  and is associated with several immune-mediated diseases  [45]. 
In the brain, the expression of CCR5 varies with developmental stage, cell type, 
and brain region [46]. Besides that, chemokines and their receptors have been 
implicated in a variety of normal functions in the brain including neurodevelopment, 
neuronal survival and intercellular communication [46]. Accordingly, abnormalities in 
chemokine functions may predispose for Schizophrenia and other psychiatric illnesses. 
In support of this, psychiatric changes such as psychotic Schizophrenia-like 
manifestations have been observed in humans upon treatment with cytokines [16, 45, 
46]. Moreover, some studies have revealed abnormalities in the secretion and blood 
levels of cytokines in Schizophrenia patients. Additionally, disturbances in chemokine 
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levels can be induced by infectious agents. In prenatal life or early childhood, this might 
have a profound effect on the development of some brain functions. In fact, the 
increased risk for Schizophrenia in adulthood associated with prenatal exposure to 
common viruses could be a consequence of cytokine disturbances induced by these. A 
retroviral etiology of Schizophrenia has also been suggested based on recent 
observations that discovered retroviral transcripts in cerebrospinal fluid from 
Schizophrenia patients [16, 45, 46].  
It is possible that the deletion allele is a modulating factor that protects against 
the generally more severe forms of EOS in individuals predisposed for psychotic 
illnesses. Such protection could stem from an altered cytokine response to common 
viruses back in early childhood or prenatal life.  If so, this may reflect a decreased 
ability of the deletion allele for clearance of common infections, leading to neuronal 
damages and predisposition for a specific form of Schizophrenia with a late onset. 
Interactions between CCR5 and viruses possessing a potential for establishing persistent 
infections with long latency periods such as retroviruses could be of particular interest 
in this respect.  
The fact that this genetic risk factor is associated to LOS when comparing to 
both general population and early-onset cases, suggests that this receptor may be 
involved in pathologic mechanisms of LOS not shared with EOS. Interestingly, as 
CCR5 is associated with neurodevelopment, neuronal survival and intercellular 
communication, this resembles the same processes attributed to the pathogenesis of 
EOS and hence this may indicate that LOS may use alternative but confluent pathologic 
pathways to generate the schizophrenic syndrome.  Worthy of note, despite CCR5 
deletion allele in not associated with Schizophrenia when patients are analyzed 
regardless of age of onset. Hence, it constitutes a risk factor specific for later forms of 
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Schizophrenia and has a simultaneous pathologic and delaying role for LOS, suggesting 
pathophysiologic proximity to the pathological processes underlying the development of 
LOS.  
 
Delaying factors 
 
The search for delaying factors of onset of Schizophrenia might have 
implications on knowledge of new therapeutic targets in patients or high-risk 
individuals, and also elucidate about potential evitable factors, and so, a way to delay 
the disorder.  
Moreover, to ascertain whether or not there are factors associated with a higher 
age of onset of symptoms constitutes another way to study the hypothesis of LOS 
being/having a component of a delay in pathological processes characteristic of EOS. A 
considerable amount of studies ascertained the existence of such factors and have 
demonstrated the existence of multiple factors, environmental or genetic, associated 
with a later onset of the disorder. These delaying factors may be divided in two types: 
(1) delaying factors with effect in the susceptibility to Schizophrenia and (2) delaying 
factors not influencing that risk. The simultaneous effect on both age of onset and the 
susceptibility to the disorder suggests a role of these factors and respective pathways in 
the pathogenic mechanisms underlying Schizophrenia. 
However, as the populations studied are basically EOS-cases, the studies on this 
subject only associate environmental or biologic factors with age within the EOS-group 
itself. Hence, it would be of great importance to study if these factors delay the onset of 
symptoms enough time so that its carriers are over-represented in the LOS group; in 
other words, if there is an association of these factors with LOS relative to EOS-cases 
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and the healthy population. By now it is pertinent to speculate that individuals who 
carry some of these factors (with or without a role in susceptibility) may be the ones 
who develop symptoms later in life and come to be diagnosed with LOS. However, if 
LOS is only a delayed form of EOS, it is expected that besides the delaying factors, the 
genetic aggregation and susceptibility remains equal. In fact, as already mentioned, LOS 
has a lower association to family history of Schizophrenia than EOS-cases, which points 
otherwise. So, if delaying factors explain the origin of LOS, some of them would have 
to play a protective role as well. Alternatively, they may explain only a fraction of LOS 
cases. 
As it is not conceivable to discuss exhaustively each one of the factors that our 
search found to be associated with later age of onset, we chose to select and discuss one 
factor that appeared to us to be the most compelling: the female gender. It is a factor 
associated with later onset of symptoms within the group of EOS-patients, it is over-
represented in LOS relative to male gender, which contrasts strongly with male 
predominance in EOS [5, 13, 17, 20]. Besides, female gender is associated with less 
severity of symptoms independently of the age of diagnosis. This may suggest that in 
some female susceptible individuals their gender may suffice to delay the initial 
manifestation until after 40 years old, when they are classified as LOS-patients; and/or 
the differences between genders might imply distinct etiopathological processes [17]. 
Some data points to the former notion and will be discussed hereafter. 
Studies based on different cultures found that female gender is associated with 
later onset, different content of delusions, less negative symptoms, more affective 
symptoms, lower average daily dose of antipsychotics, less co-morbid cigarette 
smoking, alcohol and drugs consumption and course of illness more favorable (short 
and mild terms), although they tend to exhibit a poorer outcome in the VLOSP cases, 
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particularly in terms of clinical course, longest episode and remission type [5, 17, 21]. 
This gender phenomenon is not readily explicable by women and the older patients 
being more inclined to consult or be directed toward a mental professional [5, 11]. 
Excluding the data concerning gender in VLOSP cases, the remaining data constitute a 
rational base to view female gender as a strong delaying factor in Schizophrenia 
development although it is not a protective one given that there´s no predominance of 
either gender when analyzing Schizophrenia independently of age of diagnosis.   
Given the facts above, it becomes tempting to explore the role(s) of female 
hormones in CNS. Also, the data above has served as rationale for experimental 
treatment of LOS-patients with female hormones, specifically estrogens, as already 
mentioned. In fact, several studies provided different lines of evidence relative to female 
hormones, which were pertinently reviewed by some articles and that may be 
schematized as follows: (1) epidemiological studies showed that young women are less 
likely to develop Schizophrenia than men of the same age; (2) women are more likely to 
develop LOS after menopause; (3) clinical studies showed higher psychotic symptoms 
in perimenopausal women; and (4) women at the low estrogen phase of the menstrual 
cycle tend to experiment worsening of psychotic symptoms;  (5) Three randomized 
double-blind placebo-controlled trials and an open-label showing that adding estradiol 
to women’s usual antipsychotic medications was associated with significant abatement 
of Schizophrenia symptoms; (6) A small study of men with Schizophrenia who received 
oral estradiol valerate showing a significant abatement in psychotic symptoms; (7) A 
case reporting estrogen replacement therapy alone producing remission of symptoms in 
a periclimacteric patient with LOS experiencing severe first-rank symptoms [37, 38]. 
Estrogens have some well-known effects in the CNS which include significant 
effect on modulation of dopamine and serotonin receptors, very important targets of the 
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antipsychotic drugs prescribed to schizophrenic patients and responsible for remission 
of the symptoms to the premorbid phase, as previously noted [21, 47]. So, estrogens 
have significant modulation of important effectors and pathways that seem to be 
extremely important to Schizophrenia syndrome. 
The gender differences in age of onset and clinical characteristics have been 
postulated to be due to an antipsychotic effect of estrogens. The estrogen hypothesis 
postulates that estrogen exerts a protective effect in schizophrenic women, suggesting 
that estradiol has specific antipsychotic-like effects on the symptoms of Schizophrenia, 
and an estrogen supplement might be particularly effective in the treatment and 
prophylaxis in women with LOS [38]. 
Therefore, women with a genetic vulnerability for psychotic disorder might be 
protected when they are younger, but develop psychotic disorder of a chronic type when 
their vulnerability becomes expressed later in life, under the influence of, for example, 
neurodegenerative mechanisms. On the other hand, genetically vulnerable men will be 
more likely to express their liability at an earlier age. Consequently, only men with 
lower levels of vulnerability develop psychotic disorders in old age, therefore 
displaying better outcome than their female counterparts [21]. Although this estrogen 
hypothesis may have some utility in explaining differences in mean age of onset and the 
second incidence peak in middle-aged women, it cannot explain gender differences in 
older age groups [21]. 
Interestingly, the tendency to overrepresentation of women in LOS dissipated 
when only the cases with a positive family history of Schizophrenia or other psychotic 
disorder were selected, suggesting that characteristic associated with the female gender 
may be ineffective in a background of strong individual susceptibility  [17].  
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Interestingly, a recent work studied the effect of different genotypes for the 
promoter o Neuropeptide Y, a neurotransmitor found dimished in postmortem brains of 
schizophrenic patients, on the susceptibility to develop Schizophrenia (independently of 
age of onset) [48]. Accordingly to their primary hypothesis, they verified that -485 T 
polymorphism, associated with less transcription of the gene, was associated with 
Schizophrenia susceptibility. Surprisingly, they found simultaneously an inverse 
correlation of -485 T polymorphism with symptom severity in a dose-effect fashion 
(homozygotes being the less symptomatic patients). Also, in the homozygote group of 
schizophrenic patients, a bi-modal distribution of ages of onset was present, with some 
developing EOS and others, especially women, having disease onset after 40 years of 
age, which contrasted with single peaks of onset of wild type genotypes and 
heterozygote genotype. Finally, they verified that schizophrenic symptoms developing 
below 15 years of age was highest within individuals with wild-type genotypes and 
totally absent in homozygotes for the mentioned polymorphism, further emphasizing 
this delaying effect. The findings of this study may have several implications in future 
research in the area of Schizophrenia: (1) analysis of individual susceptibility factors 
seems to be an entirely distinct parameter, namely independent of clinical severity and 
age of onset; (2) – the interaction of delaying factors (i.e. NPY seems to be), namely 
with the feminine sex, may suffice to delay diagnosis after 40 years of age; (3) – 
association of NPY with Schizophrenia independently of age of onset of 
symptomatology seems to support mechanistic overlapping between EOS and LOS. 
An important and complementary study of the hypothesis of LOS group 
including some delayed EOS cases would be analyzing specifically LOS patients and 
verify if there is an excess of the delaying factors in these groups when comparing to 
healthy population and EOS-cases, compatible with the hypothesis of delaying. Also, to 
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verify if this patients exhibit simultaneously aggregation to the same polymorphism 
well established to be associated with typical cases of Schizophrenia with be compatible 
with the same general hypothesis. One good example is to examine if LOS group is 
associated with the same polymorphisms well established to be associated with EOS 
and which constitute the rationale for the viewing of EOS as a neurodevelopmental 
disease, in example, polymorphisms of neuroregulin and dysbindin [8]. This study, 
which we think of great importance to the question of etiopathogeny of LOS relative to 
that of EOS, is not done yet 
 
Association of LOS with CNS diseases:  
Cerebrovascular pathology and Neurodegenerative Disease 
 
It is worth noting that LOS-cases stand chronologically between a form of 
Schizophrenia that has been non-lesional by definition (EOS) and the so-called VLOSP 
form, strongly associated with CNS lesions with plausible pathologic role leading to 
psychotic symptoms, those including ischemic, tumoral or other neurodegenerative 
conditions [49]. Conditions that rarely mimic Schizophrenia in early ages and that must 
be excluded before diagnosing EOS include head trauma, infections, brain tumors, 
seizures, multiple sclerosis, and Wilson's disease, endocrinopathies, autoimmune 
disorders, vitamin deficiencies and adverse reactions to prescribed medication [50]. 
Thus, a variety of secondary conditions have been proved to be associated with the 
schizophrenic syndrome in early ages as in older ages, although rare in the former. From 
this perspective, is LOS more similar to EOS or is it more similar to VLOSP in terms of 
association with CNS (primary or secondary) pathologic conditions? This question is 
not solved by the already-mentioned resemblances in neuroimaging between EOS and 
25 
LOS, once the processes that underlie these changes may have different natures. 
Moreover, there are anatomo-pathological findings in LOS that overlap with those 
characteristic of some neurodegenerative disorders [51, 52]. 
The resolution of the previous question finds its importance both in the clinical 
and etiopathogenic perspectives. On one hand, from a etiopathogenic point of view, 
studying the association of LOS with lesional processes may constitute another clue to 
the origin of this group of patients, namely if it constitutes a delayed form of the “non-
organic” EOS (if LOS is not associated with neurodegenerative conditions) or, 
alternatively, an heterogeneous group made of delayed cases and patients suffering from 
diseases affecting the CNS (not necessarily affecting distinct pathways involved in EOS 
forms).  
On the other hand, from the clinical point of view, a possible association of LOS 
with degenerative processes in the CNS would raise the possibility that Schizophrenia 
syndrome in later age constituting a symptom of neurodegenerative diseases and bring a 
prodrome of dementia in those disease-contexts. If LOS is associated with dementia that 
would be either because of association with dementiating diseases (pure statistical 
aggregation or LOS constituting a symptom group in those diseases) or through some of 
its underlying process converge/are shared with CNS degenerative dementiating 
diseases: LOS as cause of dementia vs LOS as a manifestation of neurodegenerative 
diseases.  
Scarce amount of data is available to give a solid answer when studying 
aggregation of LOS with common neurodegenerative pathologies. Nevertheless, we´ll 
review data concerning possible association of LOS with cardiovascular disease and 
primary neurodegenerative diseases like Alzheimer disease (AD), Fronto-temporal 
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dementia (FTD), Lewis Bodies dementia, Parkinson’s disease (PD) and Neurofibrillary 
Tangles-predominant senile dementia (NFT-SD). 
 
LOS and Cerebrovascular disease 
 
As already mentioned, VLOSP cases exhibit high association with CNS lesions, 
and these include cerebrovascular disease, local thrombosis or embolus. In fact, in a 
wider view, several neuropsychiatric disorders such as mood, anxiety and psychotic 
disorders occur following cerebrovascular lesions. Thus, it is pertinent to study if such 
association is also present in the LOS cases and, if so, in what extent. 
There is considerable evidence that LOS-patients tend to have high 
cardiovascular risk profile [53]. Also, psychotic symptoms are prevalent among people 
with cerebrovascular disease [49]. Despite those facts, works available are not 
concordant in their findings relative to the relationship between situations of cerebral 
hypoperfusion and LOS, with some studies that used a neuroimaging approach finding 
large areas of subcortical hyperintensities in patients with LOS and others finding no 
differences when comparing to healthy age-matched subjects [54, 55]. Interestingly, the 
studies that found association with acute or chronic ischemic disorders found also 
strong relation with disturbance of the right side of the brain.  
A recent work has analyzed a possible pathogenic role of extracranial arterial 
pathology in Late-Onset Psychiatric disorders [53]. This study has found association of 
LOS with both chronic insufficient cerebral blood flow and thromboembolic 
complications, symptomatic or clinically silent, of carotid or vertebral atherosclerotic 
disease. The plausibility for a cause-effect relationship is emphasized by the fact that 
these disorders may be solved with vascular reconstruction [56, 57]. 
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LOS, Neurodegenerative diseases and Dementia 
 
As in the case of cerebrovascular disease, psychotic symptoms are common in 
some prevalent neurodegenerative diseases, like AD, Lewis Bodies` dementia, PD and 
FTD [49, 52]. However, studies made so far, although not unanimously, have failed to 
demonstrate any association of LOS with AD, Lewis Bodies and PD [51, 58, 59]. Thus, 
if the hypothesis of LOS being associated with dementia, as already debated, is found to 
be a true association, this seems not to be due to LOS being statistically associated or 
being a prodrome of dementia in these disease-contexts, since it has no relation to them. 
If LOS may constitute a prodrome of dementia in other specific pathologic situations, 
e.g. a form of presentation of some diseases evolving to dementia, is somewhat 
different. Of particular interest is a possible association of LOS with two specific forms 
of dementia, the FTD, in which frontotemporal lobar degeneration occurs and NFT-SD 
[44, 52]. It is not known if these degenerative diseases are associated or not with LOS 
but anatomopathological studies in dementiated LOS patients showed some similarities 
with lesions found tipically with patients with FTP and NFT-SD. IN the case of NFT-
SD, the presence of neurofibrillary tangles was described in LOS, predominating in the 
entorhinal cortex, a neuroanatomic site already implicated in LOS in what concerns to 
memory impairment, affective and positive symptoms, without markedly affecting the 
personality [44]. Relative to FTP, it has been investigated if FTD-like neuropathological 
changes are present in Schizophrenia. TAR DNA-binding protein 43 (TDP 43), an 
mRNA-binding protein normally present in the nucleus and absent in neuronal nucleus 
of FTD patients was also found to absent from the nucleus of patients with LOS [52]. 
Since the known functions of this protein include regulation of gene expression (at 
levels of transcription and translation) and the modulation of neural plasticity through 
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dendritic spine growth, this could have a role in the pathogenesis of LOS, namely in 
what may lead to dementia in these patients [52]. The significance of these findings 
relates with two questions: a possible coexistence of LOS with these disease entities or, 
alternatively, pathogenic mechanisms of LOS similar in some features to some 
neurodegenerative diseases. However, one has to emphasize that anatomopatholigic 
studies comparing LOS with NFT-SD and FTP are based in series of cases and so it is 
premature to make conclusions in the current state of knowledge before larger casuistic 
are analyzed. 
 
Conclusions 
 
 There are still great difficulties in the research about LOS because of 
discrepancy in the terminology and criteria used to define it, poor research 
using this specific population and lack of uniformity in the methods used to 
assess these patients and analyze data. 
 There are well-established differences in clinical features between LOS and EOS 
patients, namely predominance of female gender, less family history, less 
premorbid personality, less severe symptomology, less dosage of neuroleptics 
required to achieve a same symptomatic remission.  These well-established 
differences give clinical utility to this subdivision of Schizophrenia. 
 Currently there is not enough data to describe the cognitive evolution in LOS. 
 Concerning etiopathogeny, current evidence support both the notions of LOS 
patients being those carrying delaying factors for EOS, like female gender and 
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the recent found -485 T promoter polymorphism of NPY, and that LOS may 
have its own pathogenic mechanisms. 
 The evidence for mechanistic overlap lies mainly in clinical resemblances 
between LOS and EOS. Findings that support discrepant mechanisms (not 
necessarily affecting different neuroanatomic bases) include recent findings 
that associate LOS (and not EOS) with specific alleles, like 32-bp delection allele 
of CCR5. 
 One recent review article found association of LOS with both chronic 
insufficient cerebral blood flow and thromboembolic complications, 
symptomatic or clinically silent, of carotid or vertebral atherosclerotic disease.  
 Currently there is no evidence that LOS may be neither a symptom of 
neurodegenerative disease nor a prodrome of dementia in these contexts. 
 Given the possibility of LOS constituting a heterogeneous group made up by 
delayed EOS cases and by distinct pathophysiologic entities, more associative 
studies analyzing this specific group are justified. Hence, subdivision of LOS 
proposed by the International Consensus remains unclear about etiopathogenic 
validity. 
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Tables 
 
Table 1  - DSM-IV-TR Diagnostic Criteria for Schizophrenia 
 
A. Characteristic symptoms of the active phase 
Two (or more) of the following, each present for a significant portion of time during a 1-
month period (or less if successfully treated):  
1. Delusions  
2. Hallucinations  
3. Disorganized speech (e.g., frequent derailment or incoherence)  
4. Grossly disorganized or catatonic behavior  
5. Negative symptoms, i.e., affective flattening, alogia, or avolition 
Note: Only one Criterion A symptom is required if delusions are bizarre or hallucinations consist of 
a voice keeping up a running commentary on the person's behavior or thoughts, or two or more 
voices conversing with each other.  
B. Social/occupational dysfunction 
For a significant portion of the time since the onset of the disturbance, one or more major 
areas of functioning such as work, interpersonal relations, or self-care are markedly 
below the level achieved prior to the onset (or when the onset is in childhood or 
adolescence, failure to achieve expected level of interpersonal, academic, or 
occupational achievement).  
C. Duration  
Continuous signs of the disturbance persist for at least 6 months. This 6-month period 
must include at least 1 month of symptoms (or less if successfully treated) that meet 
Criterion A (i.e., active-phase symptoms) and may include periods of prodromal or 
residual symptoms. During these prodromal or residual periods, the signs of the 
disturbance may be manifested by only negative symptoms or two or more symptoms 
listed in Criterion A present in an attenuated form (e.g., odd beliefs, unusual perceptual 
experiences).  
D. Schizoaffective and mood disorder exclusion 
Schizoaffective disorder and mood disorder with psychotic features have been ruled out 
because either (1) no major depressive, manic, or mixed episodes have occurred 
concurrently with the active-phase symptoms; or (2) if mood episodes have occurred 
during active-phase symptoms, their total duration has been brief relative to the duration 
of the active and residual periods.  
E. Substance/general medical condition exclusion  
The disturbance is not due to the direct physiological effects of a substance (e.g., a drug 
of abuse, a medication) or a general medical condition.  
F. Relationship to a pervasive developmental disorder  
If there is a history of autistic disorder or another pervasive developmental disorder, the 
additional diagnosis of schizophrenia is made only if prominent delusions or 
hallucinations are also present for at least a month (or less if successfully treated). 
Adapted from [6] 
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Table 2  - CID-10 Diagnostic Criteria for Schizophrenia 
 
Characteristic symptoms of the active phase 
At least one of the following, each present for a significant portion of time during a 1-
month period: 
1. Thought echo, thought insertion/withdrawal/broadcast  
2. Passivity, delusional perception 
3. Third person auditory hallucination, running commentary 
4. Persistent bizarre delusions 
 
Or 
 
Two (or more) of the following, each present for a significant portion of time during a 1-
month period:  
1. Persistent hallucinations 
2. Thought disorder 
3. Catatonic behavior 
4. Negative symptoms 
5. Significant behavior change   
Exclusion criteria 
1. Mood disorders 
2. Schizoaffective disorder 
3. Over brain disease 
4. Drug intoxication or withdrawal 
Adapted fro: [7] 
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Table 3  - Features characteristic of Late-Onset compared to Early-Onset Schizophrenia 
 
Features in common 
Features not in common Features which are 
commoner 
Features which are less 
common or less severe 
1. Visual, tactile, and 
olfactory hallucinations 
2. Third person, running 
commentary, derogatory 
auditory hallucinations 
3. Persecutory delusions 
4. Partition delusions 
 
1. Formal thought disorder 
(rare if onset >60 years) 
2. Affective flattening 
3. Affective blunting 
4. Negative symptoms 
(rare if onset >60 years) 
5. Positive symptoms 
6. Premorbid educational, 
occupational and 
psychosocial 
impairment 
7. Cognitive impairment 
(working and verbal 
memory, process 
speed, perception 
organization, cognitive 
flexibility) 
8. General 
psychopathology 
1. Female predominance 
2. No clear genetic loading 
3. Association with sensory 
deficits and social 
isolation (if onset >60 
years) 
4. Lower antipsychotic 
dosage required 
5. Better everyday 
functioning and health-
related quality of life 
Adapted from [5, 10, 13, 60, 61]  
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Table 4  - Brain Imaging characteristic of Late-Onset Schizophrenia compared to Early-
Onset Schizophrenia and normal aging 
 
Features in common with EOS  
Features not in 
common with 
EOS 
Features in 
common with 
Normal Aging 
Features not in 
common with 
Normal Aging 
1. Higher ventricle-to-brain ratio 
* 
2. Higher third ventricle volume 
* 
3. Reduction of the left 
temporal lobe* 
4. Reduction of the superior 
temporal gyrus* 
5. Later peak latency of N400 
congruity effect 
1. Larger 
thalamic 
volume * 
2. Hypoperfusion 
in frontal and 
temporal areas 
1. Larger 
thalamic 
volume * 
 
 
1. Higher ventricle-
to-brain ratio* 
2. Higher third 
ventricle volume 
3. Increase and no 
increase in D2 
receptor density 
4. Later peak latency 
of N400 congruity 
effect 
 
Functional (by PET and/or SPECT) and Structural* (by TC and/or MRI) brain imaging.  
Adapted from [5, 43, 62] 
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